Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Cougar Biotechnology
Man Max 99 years
Cougar Biotechnology, Inc
Update Il y a 4 ans
A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The proportion of patients achieving a PSA decline of >50% (PSA response) according to Prostate-Specific Antigen Working Group (PSAWG) criteria
Country
None
organs
None
Specialty
None
unknown
More information
Man
Between 18 years
and 99 years
Cougar Biotechnology
Update Il y a 4 ans
Cougar COU-AA-301 : Essai de phase 3 randomisé en double aveugle, évaluant l'efficacité d'un traitement par prédnisone avec ou sans acétate d'abiratérone, chez des patients ayant un cancer de la prostate métastatique hormonorésistant. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel...
Country
France
organs
Prostate
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Man Max 99 years
Cougar Biotechnology, Inc
Update Il y a 4 ans
A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
To evaluate the safety, tolerability and recommended dose of abiraterone acetate administered orally, by continuous once-daily administration in patients with HRPC. To determine the effect of abirat...
Country
None
organs
None
Specialty
None
unknown
More information
Man
Between 18 years
and 99 years
Cougar Biotechnology
Update Il y a 4 ans
COU-AA-302 : Essai de phase 3 randomisé, en double aveugle, évaluant l'efficacité de l'abiratérone acétate (CB7630) associé à la prednisone, chez des patients ayant un cancer de la prostate métastatique et résitant à la castration hormonale. [essai clos aux inclusions]
Etude de phase III randomisée en double aveugle contrôlée par placebo de l'Abiraterone Acetate (CB7630) plus prednisone chez les patients atteints d'un cancer de la prostate métastatique résistant à l...
Country
France
organs
Prostate
Specialty
Hormonothérapie
Essai clos aux inclusions
More information
Man Max 99 years
Cougar Biotechnology, Inc
Update Il y a 4 ans
A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
To evaluate the anti-tumor effects of CB7630 in patients with androgen independent metastatic prostate cancer (AIPC) who have failed docetaxel based chemotherapy, as measured by the proportion of pati...
Country
None
organs
None
Specialty
None
unknown
More information